GSK3B and cholangiocarcinoma: Moreover, the PDGFR inhibitor STI571 significantly inhibited PDGF-BB-induced activation of GSK3β and NF-κB, further demonstrating that GSK3β and P65 are the downstream effectors of PDGF BB/PDGFR-β in CCA cells (Fig. 8A-B).